Answers are grounded in this paper and cite their sources.
Murine experimental study demonstrates indefinite cardiac allograft survival following transient CTLA4-Ig therapy in mice, indicating donor-specific immune tolerance via costimulatory blockade.
The rejection of the transplanted allograft is dependent on T cell activation, which requires T cell receptor engagement by antigen and costimulatory signals delivered by T cell surface molecules such as CD28. CTLA4-Ig is a fusion protein that has previously been shown to block the CD28-mediated costimulatory signal and inhibit immune responses in vitro and in vivo. In this report we show that treatment of the C3H/He recipient of a BALB/c vascularized cardiac allograft with a 12-day course of CTLA4-Ig produced indefinite graft survival (> 100 days) in the majority of recipients. In addition, these recipients demonstrated donor-specific transplantation tolerance when tested with donor-specific (BALB/c) and third-party (C57BL/10) skin grafts. These results demonstrate that CTLA4-Ig can induce transplantation tolerance in the adult murine cardiac allograft model.
No takes yet. Share an insight, caveat, or question.
Pearson et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: